Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR, Foon KA, Feldman T, Schuster SJ, Svoboda J, Chow KF, Valentinetti M, Mrkulic M, Azzollini K, Gadaleta G, Bhattacharyya PK, Zenreich J, Pascual LN, Yannotti K, Kdiry S, Howlett C, Strelec L, Porter D, Bejot C, Goy A. Mato AR, et al. Among authors: strelec l. Am J Hematol. 2015 Jun;90(6):487-92. doi: 10.1002/ajh.23983. Epub 2015 Mar 30. Am J Hematol. 2015. PMID: 25691474 Free article. Clinical Trial.
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.
Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR, Loren AW, Schuster SJ, Stadtmauer EA, Svoboda J. Bair SM, et al. Among authors: strelec l. Am J Hematol. 2017 Sep;92(9):879-884. doi: 10.1002/ajh.24792. Epub 2017 Jun 9. Am J Hematol. 2017. PMID: 28512788 Free article. Clinical Trial.
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. Mato AR, et al. Among authors: strelec le. Blood. 2016 Nov 3;128(18):2199-2205. doi: 10.1182/blood-2016-05-716977. Epub 2016 Sep 6. Blood. 2016. PMID: 27601462 Free article.
Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, Ganetsky A, Nasta S, Porter DL, Svoboda J, Nabhan C, Schuster SJ. Mato AR, et al. Among authors: strelec l. Blood. 2016 Feb 25;127(8):1064-7. doi: 10.1182/blood-2015-12-686873. Epub 2015 Dec 23. Blood. 2016. PMID: 26702066 Free article. No abstract available.
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Bair SM, et al. Among authors: strelec le. Oncologist. 2019 Jul;24(7):955-962. doi: 10.1634/theoncologist.2018-0538. Epub 2018 Dec 19. Oncologist. 2019. PMID: 30568021 Free PMC article.
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Svoboda J, et al. Among authors: strelec l. Haematologica. 2021 Jun 1;106(6):1705-1713. doi: 10.3324/haematol.2019.238675. Haematologica. 2021. PMID: 32414850 Free PMC article. Clinical Trial.
Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen.
Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N. Shah NN, et al. Among authors: strelec l. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102. doi: 10.1016/j.clml.2018.11.010. Epub 2018 Nov 12. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30581160
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. Shah NN, et al. Among authors: strelec l. Br J Haematol. 2018 Feb;180(4):534-544. doi: 10.1111/bjh.15051. Epub 2017 Dec 19. Br J Haematol. 2018. PMID: 29265182 Free article.
11 results